Jeff P. Sharman, MD, on Clinical Pearls on Treatments Containing Acalabrutinib

Posted: Wednesday, December 11, 2019

Jeff P. Sharman, MD, of the Willamette Valley Cancer Institute and US Oncology Research, talks about the most significant clinical issues that practitioners need to be aware of when patients are receiving a regimen containing acalabrutinib.